[go: up one dir, main page]

Xie et al., 2008 - Google Patents

Aberrant NF-κB activity is critical in focal necrosis formation of human glioblastoma by regulation of the expression of tissue factor

Xie et al., 2008

View PDF
Document ID
3732464468778079179
Author
Xie T
Aldape K
Gong W
Kanzawa T
Suki D
Kondo S
Lang F
Ali-Osman F
Sawaya R
Huang S
Publication year
Publication venue
International journal of oncology

External Links

Snippet

Focal necrosis is a key pathologic feature that distinguishes glioblastoma from lower grade glioma. The presence of necrosis in a glioblastoma could promote its rapid growth and clinical progression. Focal necrosis of glioblastoma seems to be associated with thrombosis …
Continue reading at www.spandidos-publications.com (PDF) (other versions)

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Hybridisation probes
    • C12Q1/6883Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology

Similar Documents

Publication Publication Date Title
Ronca et al. Tumor angiogenesis revisited: regulators and clinical implications
Haemmig et al. miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas
US12139535B2 (en) Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents
Sainson et al. TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype
AU2009331955B2 (en) Biomarkers for inhibitors with anti-angiogenic activity
Dikov et al. Vascular endothelial growth factor effects on nuclear factor-κB activation in hematopoietic progenitor cells
Marfia et al. Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma
Ndiaye et al. VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness
Umetani et al. A novel cell adhesion inhibitor, K-7174, reduces the endothelial VCAM-1 induction by inflammatory cytokines, acting through the regulation of GATA
JP2012196206A (en) Met inhibitor for enhancing efficacy of radiotherapy
EP3173483A1 (en) Agents for the treatment of diseases associated with undesired cell proliferation
US20220211848A1 (en) Modulating gabarap to modulate immunogenic cell death
US20200149042A1 (en) Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
US20240280561A1 (en) Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
WO2004074511A1 (en) Diagnosis and treatment of baff-mediated autoimmune diseases and cancer
Xie et al. Aberrant NF-κB activity is critical in focal necrosis formation of human glioblastoma by regulation of the expression of tissue factor
US20210032334A1 (en) Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
US20080318241A1 (en) Methods and Systems for Detecting Antiangiogenesis
WO2019158512A1 (en) Methods for the prognosis and the treatment of glioblastoma
WO2012074842A2 (en) Compositions and methods for treating neoplasia
JP2007528208A (en) Hypoxia-inducible protein 2 (HIG2) as a potential new therapeutic target for renal cell carcinoma (RCC)
EP4213948A1 (en) Methods for treating cancers with inhibitors targeting the role of grb2 in dna repair
Taghi Khani et al. Isoform-specific knockdown of long and intermediate prolactin receptors interferes with evolution of B-cell neoplasms
US20060216731A1 (en) Methods and reagents for diagnosing and treating gliomas
Sanders et al. Activated leukocyte cell adhesion molecule impacts on clinical wound healing and inhibits HaCaT migration